Protocol GS-US-334-0139 An Expanded Access Phase 2 Study of Sofosbuvir and Ribavarin with or without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive Recurrent Hepatitis C Infection
-
Sponsor: Gilead Sciences, Inc.
Location(s): United States
Description
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.